Showing results (1-10 of 301) with videos related to
Sort By:
Pageof 31
Leukemia & Lymphoma|December 28, 2022
Plasmablastic lymphoma: from genetics to treatmentFabian Frontzek, Stephan Hailfinger, Georg LenzExpert Review of Clinical Pharmacology|October 25, 2019
Novel insights into the pathogenesis of molecular subtypes of diffuse large B-cell lymphoma and their clinical implicationsFabian Frontzek, Georg LenzCurrent Opinion in Chemical Biology|October 7, 2014
Targeting B-cell lymphomas with inhibitors of the MALT1 paracaspaseStephan Hailfinger, Georg Lenz, Margot ThomeTherapeutic Advances in Hematology|July 5, 2022
Current options and future perspectives in the treatment of patients with relapsed/refractory diffuse large B-cell lymphomaFabian Frontzek, Imke Karsten, Norbert Schmitz, et al.Blood Advances|January 10, 2024
Comparison of antibody-based immunotherapeutics for malignant hematological disease in an experimental murine modelKarin Frebel, Jörn C Albring, Anika Wohlgemuth, et al.Leukemia|November 9, 2022
mTOR inhibition amplifies the anti-lymphoma effect of PI3Kβ/δ blockage in diffuse large B-cell lymphomaWendan Xu, Philipp Berning, Tabea Erdmann, et al.Plos One|August 27, 2013
Monoubiquitination and activity of the paracaspase MALT1 requires glutamate 549 in the dimerization interfaceKatrin Cabalzar, Christiane Pelzer, Annette Wolf, et al.Cancers|May 16, 2023
Combination Treatment Targeting mTOR and MAPK Pathways Has Synergistic Activity in Multiple MyelomaKaiyan Sun, Ling Jin, Jana Karolová, et al.Leukemia|January 5, 2023
Molecular profiling of EBV associated diffuse large B-cell lymphomaFabian Frontzek, Annette M Staiger, Ramona Wullenkord, et al.The Journal of Investigative Dermatology|September 27, 2021
Impaired Autophagy in Psoriasis and Atopic Dermatitis: A New Therapeutic Target?Stephan Hailfinger, Klaus Schulze-OsthoffPageof 31